Ventus Therapeutics
PrivateLast Round
Grant
Apr 20, 2023
Total Funding Raised
$300.15M
Company Overview
Ventus Therapeutics operates in Healthcare & Life Sciences and is based in Waltham, Massachusetts. Its latest recorded funding round was a Grant round in April 2023.
Ventus Therapeutics is a biopharmaceutical company that develops small-molecule medicines targeting proteins in the inflammasome and nucleic acid-sensing signaling pathways to address acute and chronic inflammatory and immune-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ventus Therapeutics Comparables
Compare Ventus Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IFM Therapeutics | 85% | |
| Halia Therapeutics | 82% | |
| OMass Therapeutics | 82% |
For institutional investors. Book with your work email.
Ventus Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 20, 2023 | ||||
| Series C | Feb 9, 2022 | ||||
| Series B | Apr 8, 2021 | ||||
| Series A | May 6, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ventus Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series C |
| SoftBank Investment Advisers | Series C |
| RA Capital Management | Series C, Series B |
| GV | Series C, Series A, Series B |
| Cormorant Asset Management | Series C, Series B |
| Fonds de solidarité FTQ | Series C, Series B |
| SoftBank Group | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 21, 2025
Partnered with Genentech to develop small-molecule drugs.
- Sep 4, 2025
Will present at the Morgan Stanley Global Healthcare Conference.
For institutional investors. Book with your work email.
Ventus Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ventus Therapeutics's valuation, stock price, and market status.
Is Ventus Therapeutics a public or private company?
Ventus Therapeutics is a private company.
What is the current stock price of Ventus Therapeutics?
Ventus Therapeutics is a private company, so its shares have no public market price. Caplight tracks Ventus Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ventus Therapeutics worth (valuation)?
Valuation information for Ventus Therapeutics is not publicly available.
Can I buy Ventus Therapeutics stock?
Ventus Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ventus Therapeutics's last funding round?
Ventus Therapeutics's most recent funding round was Grant on April 20, 2023.
Who are the main investors in Ventus Therapeutics?
Key investors in Ventus Therapeutics include SoftBank Investment Advisers, RA Capital Management, SoftBank Group, Versant Ventures, Qatar Investment Authority.
Will Ventus Therapeutics IPO soon?
No public IPO plans have been announced for Ventus Therapeutics.
How can I track Ventus Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Ventus Therapeutics's shares on secondary markets.